|
|||||
|
|
A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease |
|
| Authors: | Tanya M. Laidlaw Katherine N. Cahill Juan Carlos Cardet Katherine Murphy Jing Cui Brittney Dioneda Parul Kothari Benjamin A. Raby Elliot Israel Joshua A. Boyce |
| Affiliation: | 1. Department of Medicine, Harvard Medical School, the Division of Rheumatology, Immunology and Allergy, Brigham and Women''s Hospital, and the Jeff and Penny Vinik Center, Boston, Mass;2. Division of Rheumatology, Immunology and Allergy, Brigham and Women''s Hospital, Boston, Mass;3. Division of Pulmonary and Critical Care, Brigham and Women''s Hospital, Boston, Mass;4. Department of Medicine, Harvard Medical School, Boston, Mass, and the Pulmonary and Critical Care Division, Brigham and Women''s Hospital, Boston, Mass |
| Abstract: | |
| Keywords: | Aspirin-exacerbated respiratory disease double-blind randomized placebo-controlled crossover trial prasugrel Samter triad NSAID-exacerbated respiratory disease leukotrienes AERD Aspirin-exacerbated respiratory disease Cr Creatinine CysLT Cysteinyl leukotriene Type 1 CysLT receptor Fraction of exhaled nitric oxide 5-LO 5-Lipoxygenase PD2 Increase in TNSS of 2 points PG Prostaglandin PGD-M PRP Platelet-rich plasma Type 12 purinergic TNSS Total Nasal Symptom Score Corresponding author: Tanya M. Laidlaw, MD, Brigham and Women's Hospital, 60 Fenwood Rd, Building of Transformative Medicine, Rm 5002M, Boston, MA 02115. |
| 本文献已被 ScienceDirect 等数据库收录！ | |